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tures via interactions with microbes in the gut. The S100 cal-
cium binding proteins S100A8 and S100A9, and their
extracellular complex form, S100A8–A9, are found in high
amounts in human breast milk. We studied levels of S100A8–
A9 in fecal samples (also called fecal calprotectin) from new-
borns and during infancy, and their effects on development of
the intestinal microbiota and mucosal immune system.
METHODS: We collected stool samples (n ¼ 517) from full-
term (n ¼ 72) and preterm infants (n ¼ 49) at different
timepoints over the first year of life (days 1, 3, 10, 30, 90,
180, and 360). We measured levels of S100A8–A9 by
enzyme-linked immunosorbent assay and analyzed fecal
microbiomes by 16S sRNA gene sequencing. We also ob-
tained small and large intestine biopsies from 8 adults and
10 newborn infants without inflammatory bowel diseases
(controls) and 8 infants with necrotizing enterocolitis and
measured levels of S100A8 by immunofluorescence micro-
scopy. Children were followed for 2.5 years and anthropo-
metric data and medical information on infections were
collected. We performed studies with newborn C57BL/6J
wild-type and S100a9–/– mice (which also lack S100A8).
Some mice were fed or given intraperitoneal injections of
S100A8 or subcutaneous injections of Staphylococcus aureus.
Blood and intestine, mesenterial and celiac lymph nodes
were collected; cells and cytokines were measured by flow
cytometry and studied in cell culture assays. Colon contents
from mice were analyzed by culture-based microbiology
assays. RESULTS: Loss of S100A8 and S100A9 in mice
altered the phenotypes of colonic lamina propria macro-
phages, compared with wild-type mice. Intestinal tissuesfrom neonatal S100-knockout mice had reduced levels of
CX3CR1 protein, and Il10 and Tgfb1 mRNAs, compared with
wild-type mice, and fewer T-regulatory cells. S100-knockout
mice weighed 21% more than wild-type mice at age 8 weeks
and a higher proportion developed fatal sepsis during the
neonatal period. S100-knockout mice had alterations in their
fecal microbiomes, with higher abundance of Enterobacteri-
aceae. Feeding mice S100 at birth prevented the expansion
of Enterobacteriaceae, increased numbers of T-regulatory
cells and levels of CX3CR1 protein and Il10 mRNA in intes-
tine tissues, and reduced body weight and death from
neonatal sepsis. Fecal samples from term infants, but not
preterm infants, had significantly higher levels of S100A8–A9
during the first 3 months of life than fecal samples from
adults; levels decreased to adult levels after weaning. Fecal
samples from infants born by cesarean delivery had lower
levels of S100A8–A9 than from infants born by vaginal de-
livery. S100 proteins were expressed by lamina propria
macrophages in intestinal tissues from infants, at higher
levels than in intestinal tissues from adults. High fecal levels
of S100 proteins, from 30 days to 1 year of age, were
associated with higher abundance of Actinobacteria and
Bifidobacteriaceae, and lower abundance of Gammaproteo-
bacteria—particularly opportunistic Enterobacteriaceae. A
low level of S100 proteins in infants’ fecal samples associ-
ated with development of sepsis and obesity by age 2 years.
CONCLUSION: S100A8 and S100A9 regulate development of
the intestinal microbiota and immune system in neonates.
Nutritional supplementation with these proteins might aide in
development of preterm infants and prevent microbiota-
associated disorders in later years.
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
After birth, the immune system develops via interactions
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olonizing microbes provide the newborn immunewith microbes in the gut. S100A8 and S100A9 (also
called calprotectin) are immune-stimulatory S100
calcium binding proteins present in high amounts in
breast milk.
NEW FINDINGS
S100A8 and S100A9 regulate development of the
intestinal microbiota and immune system in neonates.
LIMITATIONS
Further studies are needed to determine the effects of
S100 proteins in humans and in newborns.
IMPACT
Nutritional supplementation with S100 proteins might aide
in development of preterm infants and prevent













ATCsystem with crucial instructing information that in-
duces postnatal maturation of immunity.1,2 This co-
development ideally results in a balanced homeostasis
between the host and the microbiota,3 whereas alterations
predispose individuals to inflammatory and metabolic dis-
eases.4–7 Specific microbiota compositions have been
described to precede necrotizing enterocolitis (NEC)8 in
preterm infants and to be important direct sources of
sepsis-causing bacterial translocation.9,10 Except for full-
term birth, vaginal delivery (VD), and breastfeeding,11–16
little is known about what host factors influence the inter-
play between intestinal immunity and initial gut coloniza-
tion to ensure developing homeostasis.
In healthy neonates, high serum concentrations of the
endogenous Toll-like receptor 4 ligands S100A8 and
S100A9 induce a state of microbial hyporesponsiveness in
blood monocytes, also described as “stress tolerance.”17–19
Physiologically, they form a heterodimer complex
(S100A8-A9) known as calprotectin.20,21 Later in life, when
acutely released during inflammatory settings, S100A8-A9
exerts primarily amplifying effects and serves as biomarker
of inflammation, for example, fecal calprotectin (hereafter
“fS100A8-A9”) in inflammatory bowel disease (IBD).22
Breast milk contains extremely high levels of S100A8-A923
and fS100A8-A9 levels are high in healthy breast-fed in-
fants.24 After birth, blood-derived (BD) monocytes replace
yolk sac–derived intestinal macrophages and differentiate
into tissue-resident lamina propria macrophages
(LPMPs).25–27 The invasion of S100-primed neonatal
monocytes together with the high local supply at the luminal
site via breast milk prompted us to speculate about S100A8-
A9 playing an important role for the postnatal development
of intestinal immunity and microbial colonization.
We found that high levels of fS100A8-A9 in the neonatal
gut induce a regulatory LPMP phenotype permissive for the
expansion of regulatory T cells (Tregs), which promotes a
favorable development of the gut microbiota. The clinical
relevance is corroborated by strong associations of neonatal
fS100A8-A9 deficiency with dysbiosis-linked diseases like
NEC, sepsis, and obesity, which can experimentally be pre-
vented by a single nutritional supply of S100A8 at birth.* Authors share co-first authorship.
Abbreviations used in this paper: BD, blood-derived; BMI, body mass in-
dex; CS, cesarean section; CX3CR1, chemokine (C-X3-C motif) receptor 1;
IL-1b, interleukin-1 beta; IP, intraperitoneally; LI, large intestine; LOS, late-
onset sepsis; LPMP, lamina propria; LPS, lipopolysaccharide; MOD, mode
of delivery; NEC, necrotizing enterocolitis; SI, small intestine; TGF-b,
transforming growth factor beta; TNF-a, tumor necrosis factor-alpha;
Treg, T-regulatory cell; VD, vaginal delivery; WT, wild-type; YS, yolk sac.
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Stool samples were collected from 2 birth cohorts of healthy
term (n ¼ 72, Supplementary Table 1) and preterm (n ¼ 49, 23
to 32 gestational weeks, Supplementary Table 2) infants pro-
spectively enrolled at the Hannover Medical School respective
the University Hospital of Lübeck. Late-onset sepsis (LOS) was
defined as sepsis starting after 72 hours of life. Biopsies of
human small intestine (SI) and large intestine (LI) were ob-
tained from n ¼ 8 adults and n ¼ 10 newborn infants without
underlying IBD (controls) and n ¼ 8 patients with NEC
(Supplementary Table 3). Written informed consent wasobtained from all parents and donors. For details see
Supplementary Experimental Procedures.
Mice and Mouse Studies
Mouse strains housed under specific pathogen-free condi-
tions were the Foxp3-eGFP reporter mouse B6.Cg-Foxp3 tm1
Mal/J for the isolation of naïve CD4þ T cells, and the C57BL/6J
wild-type (WT) mouse and the S100a9–/– mouse28 (also defi-
cient for S100A8 due to the dependency of the post-
transcriptional stability of S100A8 on the presence of
S100A928,29 and the failure to form heterocomplexes20,21) to
harvest colons and mesenterial and celiac lymph nodes. In
indicated experiments, S100a9–/– pups were injected intraper-
itoneally (IP) or fed per os within 24 hours after birth with
recombinant murine S100A8 or phosphate-buffered saline
(controls). For details regarding mating and cross-fostering
settings, cell isolation, immunofluorescence microscopy of tis-
sue samples, and of murine fecal samples, see Supplementary
Experimental Procedures.
Murine Model of Neonatal Sepsis
At the age of 3 days, mice were infected subcutaneously
with 7  104 colony-forming units (CFU) of Staphylococcus
aureus and returned to their mothers. Mice were monitored
over 80 hours for survival or killed 24 hours after infection to
harvest blood for cytokine measurements and organs. Bacterial


















ATburden was determined as described previously17 by plating
homogenates of lungs and livers onto blood-agar plates and
counting bacterial colonies after 18 hours of incubation at 37C.
Cell Culture Assays
LPMPs were ex vivo incubated with lipopolysaccharide
(LPS) or phosphate-buffered saline and processed for gene
expression studies. LPMPs were co-cultured with naïve T cells
from Foxp3-eGFP reporter mice to assess their Treg-inducing
capacity. For details of cell culture conditions, flow cytometry
and quantitative reverse transcriptase polymerase chain reac-
tion, see Supplementary Experimental Procedures.
16S rRNA Gene Bacterial Profiling
16S rRNA gene profiling of human fecal samples was per-
formed as described previously.10 DNA was isolated using the
PowerSoil DNA Isolation Kit (MOBIO, Carlsbad, Canada) with an
additional 1.5-hour Protease K incubation before the first
centrifugation step. From each DNA sample, the V3-V4 region of
the 16S rRNA gene was amplified using primers spanning the
V3-V4 hypervariable regions (Supplementary Table 4). PCR
including quantification of amplicons and library preparation
was performed as described elsewhere.30 Equimolar amounts
of the correct-sized amplicons were pooled for sequencing.
Sequencing including negative extraction controls was per-
formed on an Illumina MiSeq sequencer using the MiSeq Re-
agent Kit v3 (600 cycles) (Illumina, San Diego, CA). For details
of bioinformatics of 16S rRNA gene sequencing data and nested
model comparisons, see Supplementary Experimental
Procedures.
Cytokine Studies
Plasma levels of tumor necrosis factor-alpha (TNF-a) and
interleukin-1 beta (IL-1b) were measured by using murine
LEGENDplex assays (BioLegend, San Diego, CA). FACS Canto II
flow cytometer was used for measurements and LEGENDplex
Data Analysis Software v7.0 (BioLegend) for data analysis.
Statistical Analysis
Statistically significant P values are indicated by asterisks.
Tests are specified in figure legends. For details of statistical
tests, see Supplementary Experimental Procedures.
Data Availability
16S rRNA sequencing files were submitted to the National
Center for Biotechnology Information Sequence Read Archive=
Figure 1. Postnatal abundance of S100A8-A9 in the human inte
at indicated ages from a cohort of (A,C) healthy term infants (n
logarithmic scale represent means ± SEM. *P < .05, ****P < .0
normal adult fS100A8-A9 levels (50 mg/g). (C, D) Regression of
shaded 95% confidence interval). P value indicates differences
with/without MOD as predictor beyond age). (E, F) Top, represe
tissue samples from individuals without underlying intestinal infla
nuclei (with 40,6-diamidino-2-phenylindole [DAPI]; blue). Bottom,
in S100A8-CD68þ LPMPs (green bar section) and S100A8þCD68
counts in 4 high-power fields of n ¼ 4 adult and n ¼ 6 neonatal
(F). *P <.05, **P <.005 (Mann-Whitney U test).(www.ncbi.nlm.nih.gov/sra) and are available with BioProject
accession number PRJNA514340.Results
Abundant S100A8-A9 in the Gut of Healthy
Infants
To obtain a comprehensive picture of fS100A8-A9 levels
in newborn infants, 517 stool samples collected from a
birth cohort of 72 healthy term infants (Supplementary
Table 1) and 49 preterm infants (Supplementary Table 2)
were analyzed. In term infants, fS100A8-A9 levels are
significantly higher during the first 3 months of life
compared with normal adult values and normalize along
with weaning until the end of the first year (Figure 1A). In
preterm infants, initial fS100A8-A9 levels are significantly
lower than in term infants (Supplementary Figure 1A), but
increase during the first month of life (Figure 1B). In both
cohorts, fS100A8-A9 levels were dependent on the mode of
delivery (MOD) with higher levels after VD than cesarean
section (CS) (Figure 1C and D), particularly after primary CS
(Supplementary Figure 1B). In term infants, the MOD im-
pacts on fS100A8-A9 levels only in the first week of life, but
in preterm infants until the third week of life
(Supplementary Figure 1C and D). Breast milk is one
important source of fS100A8-A9 in newborn infants.23,24 To
investigate whether S100A8-A9 is also produced endoge-
nously in the neonatal gut, we used human SI and LI tissue
samples of newborn and adult patients without underlying
IBD. Under these physiologic conditions, S100-protein
expression is detectable in LPMPs but not in intestinal
epithelial cells, with the proportion of S100A8-expressing
LPMPs being significantly higher in the SI (Figure 1E) and
LI (Figure 1F) of neonates compared with adults. Thus, the
gut of healthy neonates is exposed to high amounts of
S100A8-A9, while deficient states are particularly observed
in preterm infants delivered by CS.High fS100A8-A9 During Infancy Supports
Developing Gut Eubiosis
To assess whether physiologically high fS100A8-A9 in
neonates plays a role for the development of the gut
microbiome we generated 16S rRNA gene profiles of 414
stool samples from the term infant cohort. Overall diversity
of gut microbiota composition significantly increases during
the first year of life (Figure 2A) and follows knownstinal tract. (A–D) S100A8-A9 levels in fecal samples collected
¼ 72) and (B, D) preterm infants (n ¼ 48). (A, B) Bars on a
001 (Kruskal-Wallis test). Dotted line indicates the cutoff for
fS100A8-A9 levels subgrouped according to the MOD (gray-
between both groups (likelihood ratio tests of nested models
ntative images of human adult and neonatal SI (E) and LI (F)
mmation immunostained for S100A8 (red), CD68 (green), and
total number of CD68þ LPMPs (blue dotted bar) differentiated
þ LPMPs (red bar section). Values represent means ± SEM of
SI samples (E) and n ¼ 4 adult and n ¼ 4 neonatal LI samples
Figure 2. High fS100A8-A9 levels are associated with an eubiotic infant gut state. (A–C) 16S ribosomal RNA (rRNA) gene
sequencing data determined in 414 stool samples collected from 72 human term infants (day 1: n ¼ 57, day 3: n ¼ 51, day 10:
n ¼ 66, day 30: n ¼ 63, day 90: n ¼ 59, day 180: n ¼ 62, day 360: n ¼ 56). (A) Shannon index of individual 16S rRNA profiles
and linear regression line (gray-shaded 95% confidence interval) across the first year of life. Significance (P) of changes over
time (general mixed regression model treating subject as a random effect for stratification, analysis of variance F-test). (B)
Mean relative abundance of bacterial taxa at class level. (C) Cuneiform plot (marker direction and hue shows effect direction,
marker intensity effect size) of gut bacterial taxa at class level significantly (Spearman or Mann-Whitney U false discovery rate
[FDR] <0.1, nested model test FDR <0.1) and strongly (absolute Spearman rho or Cliff’s delta effect size >0.2) impacted by
age, MOD, or fS100A8-A9 across infancy (30 days to 1 year), when adjusting (nested mixed effects model comparison) for
each of the other 2 variables. Bold markers fulfill significance criteria, gray-edged markers do not and are shown for com-
parison only.





Figure 3. Enterally supplied immunoregulatory S100-alarmins and the gut microbiota. (A,B) Fecal samples collected from the
WT and S100a9–/– offspring at indicated ages (each n ¼ 10–13). (A) Total bacterial counts cultured in aerobic conditions. CFU,
colony-forming units. *P < .05 (unpaired t-test). (B) Proportion of mice with Enterobacteriaceae-positive feces (each n ¼ 8–13).
(C, D) The offspring of WT and S100a9–/– (KO) mothers was co-fostered and cross-fostered. (C) Experimental setup. (D)
Proportion of mice with Enterobacteriaceae-positive feces at day 10 (each n ¼ 8–11). (E,F) Proportion of S100a9–/– mice with
Enterobacteriaceae-positive feces at day 10 after (E) feeding or (F) IP injection of S100A8 or phosphate-buffered saline (PBS)
(Ctrl) within 24 hours after birth (each n ¼ 22–25). *P <.01, **P <.005, n.s., not significant (sign tests).













ATdynamics in bacterial classes,2,11,16 most prominent the in-
crease of Actinobacteria, Bacteroidia, and Clostridia and the
decrease of Bacilli and Gammaproteobacteria (Figure 2B).
To test the impact of fS100A8-A9 and MOD on longitudinal
microbiome features nested model comparisons were per-
formed using strict filter criteria for differential taxon
abundances while accounting for confounding influences.
The initial colonization pattern (birth to 10 days), especially
that of Bacilli, Bacteroidia, Clostridia, and Gammaproteo-
bacteria, is primarily determined by the MOD but not
fS100A8-A9 (Supplementary Figure 2 and Supplementary
Table 5). However, after that period, MOD impact only re-
mains detectable for the expansion of Clostridia. In contrast,high fS100A8-A9 levels during entire infancy (30 days to 1
year) are linked to a specific microbiome signature corre-
lating with a higher abundance of Actinobacteria and anti-
correlating with the abundance of Gammaproteobacteria
(Figure 2C and Supplementary Table 5). At the family level,
fS100A8-A9 has particular impact on the expansion of
Bifidobacteriaceae, and in turn contributes to the reduction
of Enterobacteriaceae in the infant’s gut (Supplementary
Table 5). Prediction models based on these gut microbial
communities revealed significant effects on the abundance
gut metabolic pathways of fS100A8-A9 after the first 10
days of life, but not of the MOD (Supplementary Table 5),
with fS100A8-A9 promoting production and inhibiting


















ATdegradation of short-chain fatty acids (Supplementary
Figure 3). The data suggest that S100-alarmins are crucial
for promoting a favorable infant gut state of abundant
Actinobacteria-like Bifidobacteriaceae and growth restric-
tion of Gammaproteobacteria including pathobiont Entero-
bacteriaceae, resulting in a shift toward health-promoting
gut metabolic functions.
To get further mechanistic insight, we performed mouse
experiments using WT and S100a9–/– mice. Dams were co-
housed to ensure comparability of the mother’s gut micro-
biota and separated on day 18 of pregnancy shortly before
giving birth. In the WT and S100a9–/– offspring, no striking
difference is detectable in the overall fecal bacterial count
(Figure 3A). However, while cultivable amounts of Entero-
bacteriaceae, mainly Escherichia coli based on its charac-
teristic morphology on MacConkey agar, in the S100a9–/–
offspring are already detectable from day 1 on, they are not
observed in WT mice before weaning (day 21) (Figure 3B).
In a cross-fostering setting, early-life overgrowth of
Enterobacteriaceae is completely abrogated in S100a9–/–
neonates fostered by WT mothers, while in WT neonates
fostered by S100a9–/– mothers, cultivable amounts of
Enterobacteriaceae get traceable already on day 10
(Figure 3C and D). Thus, endogenous production of S100A8-
A9 alone is insufficient in order to achieve full effect, which
instead requires supplementation by S100-alarmins via
breast milk, whereas the effect of breast milk-derived
S100A8-A9 alone is full restriction of Enterobacteriaceae
growth.
To exclude direct antimicrobial effects from S100-
alarmins by chelating Mn2þ and Zn2þ,23,31,32 we supplied
S100a9–/– neonates with the S100A8 homodimer that lacks
binding sites for divalent metal ions.21,32,33 A one-time
feeding of S100A8 after birth is sufficient to successfully
limit the subsequent expansion of Enterobacteriaceae
(Figure 3E) suggesting that the S100-priming of neonatal
intestinal immunity is important for the microbiota-shaping
effect, whereas the systemic administration of S100A8 at a
dose strongly immunoregulatory for blood monocytes17,18
has no significant impact on the abundance of Enterobac-
teriaceae (Figure 3F).
Collectively, our findings clearly reveal that high
fS100A8-A9 in infants affects the mutual relationship be-
tween the host and the gut microbiota in a beneficial
manner by restricting the growth of pathobiont Gammap-
roteobacteria, particularly Enterobacteriaceae including E=
Figure 4. Differential programming of WT and S100a9–/– LPMPs
were analyzed by flow cytometry. (A) Proportion of yolk sac (Y
and BD-LPMPs. (C) CX3CR1 level on YS-LPMPs and BD-LPM
<.005 (post hoc unpaired t-test) (each n ¼ 4–11). MFI, mean
images of LI tissue samples from day 10 WT and S100a9–/– mic
(DAPI; blue). Scale bar, 50 mm. Lower left panels, single color
CX3CR1 expression by F4/80þ LPMPs. Box plots show median
per F4/80þ region of interest (ROI) determined in 14 randomly se
indicated genes in LPMPs isolated from the LI of WT and S100a
and (F) ex vivo LPS-induced fold changes of expression. Plots re
< .005 (post hoc unpaired t-test).coli, and promoting the colonization with eubiont Actino-
bacteria including Bifidobacteriaceae.
S100-alarmins Regulate LPMPs
To explore how S100A8-A9 primes intestinal immunity,
we isolated colonic LPMPs from WT and S100a9–/– mice at
day defined ages (Supplementary Figure 4A and B).
Morphologically, there are no differences between WT and
S100a9–/– LPMPs (Supplementary Figure 4C) or numeric al-
terations in the proportions or the replacement of yolk sac
LPMPs by BD-LPMPs27 (Figure 4A and Supplementary
Figure 4B). The same holds true for the proportion of che-
mokine (C-X3-C motif) receptor 1 (CX3CR1)-positive LPMPs
(Figure 4B). However, the mean expression of CX3CR1 is
significantly lower on S100a9–/– BD-LPMPs compared with
WT BD-LPMPs during the neonatal period and adolescence
(Figure 4C and D). Next, freshly isolated LPMPs were used to
capture the in vivo tuned baseline of gene expression
(Figure 4E). In S100a9–/– LPMPs, Tnf is significantly higher
expressed on day 3, but lower on day 10 and day 21 than in
WTLPMPs, whereas the expression of Il1b is comparable. The
microbial responsiveness of the LPMPswas studiedby ex vivo
LPS stimulation (Figure 4F). On day 3, S100a9–/– LPMPs
respond with a significantly stronger expression of Tnf and
Il1b, whereas from day 10 the pattern switches to a signifi-
cantly reduced inducibility of these proinflammatory genes
comparedwithWTLPMPs.During thefirst postnatal days, the
extreme high levels of S100A8-A9 apparently tolerize the LPS
response of LPMPs, whereas with increasing age while basal
S100A8-A9 levels decrease its amplifier function takes effect
on induction.19,34–36 In contrast, the regulatory genes Il10 and
transforming growth factor-b (Tgfb1) show nearly constant
basal (Figure 4E) as well as LPS-induced (Figure 4F)
expression deficits in S100a9–/– LPMPs compared with WT
LPMPs, pointing to an important impact of S100A8-A9 on the
regulatory phenotype of LPMPs.
S100-primed LPMPs Promote the Expansion of
Tregs
CX3CR1, IL-10, and TGF-b have been identified as
important triggers for the expansion of Tregs.37–40 We
therefore performed age-dependent analyses
(Supplementary Figure 5A and B) revealing that the initial
influx of Tregs into the colonic lamina propria and their
proportion in mesenterial lymph nodes and celiac lymph. (A–C) LPMCs isolated from the LI of WT and S100a9–/– mice
S)-LPMPs and BD-LPMPs. (B) Percent CX3CR1þ YS-LPMPs
Ps. Bars represent means ± SEM. *P <.05, **P <.01, ***P
fluorescence intensity. (D) Upper left panels, representative
e immunostained for CX3CR1 (red), F4/80 (green), and nuclei
stainings of the dotted zoom-out. Scale bars, 10 mm. Right,
s, interquartile ranges and total ranges of the MFI of CX3CR1
lected images. *P < .01 (unpaired t-test). (E, F) Expression of
9–/– mice at indicated ages. (E) Basal expression level (in vivo)
present means ± SEM (each n ¼ 3–6). *P < .05, **P < .01, ***P





Figure 6. S100-priming of the neonatal gut modulates the development of mucosal immunity. (A–J) LPMCs from S100a9–/–
neonates supplemented within the first 24 hours after birth with S100A8 or phosphate-buffered saline (PBS) (controls, Ctrl) via
the (A-E) IP route or (F–J) enteral (per os) route. (B, G) CX3CR1 (mean fluorescence intensity [MFI]) on BD-LPMPs (each n ¼ 11–
18) and (C, H) fractions of CD3þCD4þFoxP3þ Tregs in CD3þ T cells (each n ¼ 6–10). (D, I) Relative basal expression (in vivo)
and (E, J) ex vivo LPS-induced fold changes of expression of indicated genes in day 10 LPMPs from S100a9–/– neonates
supplemented after birth IP (D, E, each n ¼ 7–8) or per os (I, J, each n ¼ 6–7) with S100A8 or PBS (Ctrl). (K–N) The offspring of
WT and S100a9–/– mothers were co-fostered and cross-fostered (each group n ¼ 4–7). (K) Experimental setup. (L) CX3CR1
(MFI) on BD-LPMPs, (M) proportions of CD3þCD4þFoxP3þ Tregs in CD3þ T cells and (N) relative basal expression of
indicated genes in day 10 LPMPs. Plotted are means ± SEM. *P < .05, **P < .01, ***P < .005, ****P < .0005 (post hoc unpaired
t-test).













ATnodes are comparable in WT and S100a9–/– mice. However,
the subsequent expansion of Tregs in the colon is signifi-
cantly impaired in adolescent S100a9–/– mice compared
with WT mice (Figure 5A–D). In co-culture, Tregs are
significantly better inducible from naïve T cells in the
presence of WT LPMPs than S100a9–/– LPMPs (Figure 5E
and F). Supplementation of TGF-b increases the overall yield
of Tregs that nevertheless still remains lower in co-culture
with S100a9–/– LPMPs compared with WT LPMPs
(Figure 5G). The additional supplementation of IL-10,
however, compensates for the deficient Treg-inducing ca-
pacity of S100a9–/– LPMPs (Figure 3H). These findings=
Figure 5. S100a9–/– LPMPs do not support the expansion of Tre
and (B) absolute Treg numbers in the lamina propria of the LI, m
harvested fromWT and S100a9–/– mice. Plots represent means ±
test). (C, D) Immunofluorescence microscopy of Tregs in LI tissue
days. (C) Representative images, immunostained for CD4 (blue)
mark CD3þCD4þFoxP3þ Tregs. (D) Means ± SEM of the fraction
.005 (post hoc unpaired t-test). (E–H) Naïve T cells isolated from
alone or with colonic WT or S100a9–/– LPMPs in the presence
portions of induced Tregs at T cell:LPMP ratios of 10:1 and 5:1. (
TGF-b (G) or TGF-b and IL-10 (H) (T cell:LPMP ratios 5:1). Bars
.01, ***P < .001 (post hoc analysis of variance t-tests).suggest that the S100A8-A9–induced LPMP phenotype
promotes the postnatal development of Tregs in the colonic
mucosa particularly by providing IL-10.Imprinting of Neonatal Gut Immunity by S100-
alarmins
S100A8 homodimers are the most immunoactive form of
S100-alarmins.17–20 We tested the immunomodulatory po-
tential of a single IP injection or a one-time feeding of
S100A8 within 24h after birth on gut immunity in S100a9–/–
pups (Figure 6A and F). From day 10 on, we observedgs. (A) Proportion of CD3þCD4þFoxP3þ Tregs in CD3þ T cells
esenteric lymph nodes (mLN) and celiac lymph nodes (cLN)
SEM (each n ¼ 5–8). *P < .05, **P < .01 (post hoc unpaired t-
samples from WT and S100a9–/– mice aged 3, 10, 21, and 56
, CD3 (green), and FoxP3 (red). Scale bar, 50 mm. Arrowheads
of CD3þCD4þFoxP3þ Tregs in CD3þ T cells. *P < .05, **P <
spleens of Foxp3-eGFP reporter mice were cultured for 4 days
of anti-CD3/CD28 and IL-2. (E) Experimental setup. (F) Pro-
G, H) Proportions of induced Tregs with additional presence of
represent means ± SEM (each group n ¼ 3–5) *P < .05, **P <
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ATsignificantly higher level of CX3CR1 on LPMPs after S100A8
supplementation compared with control mice, independent
of the route of administration (Figure 6B and G). Likewise,
Tregs expand significantly better after S100A8 application,
particularly via the enteral route (Figure 6C and H). S100A8
effects on the transcriptional programming were assessed
on day 10 when the baseline expression of Il10 and Tgfb1
and the LPS-inducibility of Tnf, Il1b, and Il10 are impaired in
S100a9–/– LPMPs (Figure 4E and F). S100A8 given IP has no
effect on the basal expression of Il10 and Tgfb1 (Figure 6D)
and only improves the LPS-inducibility of Tnf and Il1b
(Figure 6I). However, postnatal one-time feeding of S100A8
significantly increases the basal expression level of Il10
(Figure 6E) and enhances the responsiveness of all LPS-
inducible genes, that is, Tnf, Il1b and Il10 (Figure 6J).
Cross-fostering experiments (Figure 6K–N) corroborated
the importance of the enteral supply of S100-alarmins.
Breast milk of WT mothers alone induces a full regulatory
LPMP phenotype in S100a9–/– neonates with respect to
CX3CR1 levels and Tnf, Il10, and Tgfb1 expression and
proper Treg expansion comparable to the co-fostered WT
offspring. Instead, comparing WT neonates fostered by
S100a9–/– mothers with co-fostered WT neonates reveals
that sole endogenous production of S100A8-A9 leads only to
a deficient expression of Tnf and Tgfb1 and less strong Treg
expansion. Collectively, these findings demonstrate that the
perinatal enteral supply of S100A8 regulates the inflam-
matory responsiveness of LPMPs which promotes the












High fS100A8-A9 During Infancy Prevents
Dysbiosis-linked Diseases
NEC in preterm infants is preceded by gut dysbiosis with
an early abundance of Enterobacteriaceae.8,10 We deter-
mined the proportion of S100A8-expressing LPMPs in in-
testinal tissue samples obtained from NEC patients in
comparison with age-matched controls (Supplementary
Table 3). In NEC samples, barely any S100A8þ LPMPs are
found compared with the high number of S100A8-
expressing LPMPs in neonates without underlying intesti-
nal inflammation (Figure 7A). The lack of enteral supply of=
Figure 7. Implications of neonatal intestinal S100-priming for h
noninflammatory-diseased (control) and NEC-diseased human n
(red), CD68 (green), and nuclei (blue). Right panels, total numbe
(green bar) and S100A8þCD68þ LPMPs (red bar). Values represe
5 NEC SI, n ¼ 4 control LI, and n ¼ 3 NEC LI. *P <.05, **P <.00
levels in preterm newborns without (n ¼ 18) or with later occurre
ranges ± SD, *P < .05 (likelihood ratio test of nested models w
age included as covariate in both models). (C–F) S100a9–/– neon
(PBS) (Ctrl) followed by sepsis induction on day 3 by subcutane
(Ctrl n ¼ 8, S100A8 n ¼ 9). **P < .005 (Mantel-Cox test). (E) Plas
(Ctrl n ¼ 7, S100A8 n ¼ 9) 24 hours after infection. Bars represe
.01, ***P < .005, ****P < .001 (unpaired t-test). (G) Regression o
indicated ages (each group n ¼ 14–40 with equal sex distribution
of adult (day 56) male WT and S100a9–/– mice co-fostered or cr
**P < .005, ***P < .0001 (unpaired t-test). (I) Multivariable, confou
correlation between the mean of fS100A8-A9 from day 1 to 10 an
term infants. Best fit dotted regression line and gray-shaded SES100A8-A9 due to the common practice of fasting in
imminent NEC and the reduced endogenous production of
S100A8-A9 in such patients suggest that S100-alarmins
protect against NEC.
Another early-life disease associated with gut dysbiosis
is neonatal LOS.9,10 In the cohort of preterm infants,
fS100A8-A9 levels preceding LOS are significantly lower
than corresponding levels in infants without later sepsis
(Figure 7B). fS100A8-A9 levels below 28 mg/g are associ-
ated with a 14-fold higher LOS risk than levels above 153
mg/g (Supplementary Table 6). In a murine model of S
aureus–induced infection, we tested the prevention of
neonatal sepsis by enterally supplied S100A8 (Figure 7C).
One-time feeding of S100A8 at birth significantly lowers the
death rate of S100a9–/– neonates from later sepsis
(Figure 7D) along with an effective restriction of the cyto-
kine response (Figure 7E) and bacterial burden (Figure 7F).
In the long term, gut dysbiosis has been identified as risk
factor for the development of obesity.7,41,42 We find com-
parable birth weights in WT and S100a9–/– pups, however,
from day 10 on a significantly stronger weight gain in
S100a9–/– mice compared with WT mice (Figure 7G).
Fostering of S100a9–/– neonates by WT mothers signifi-
cantly restricts the weight gain resulting in adult body
weights comparable to that of co-fostered WT mice. In turn,
WT mice that are fostered by S100a9–/– mothers end up
with significantly higher body weights than the co-fostered
WT offspring (Figure 7H). In humans, the body mass in-
dex (BMI) is a predictive value for early childhood obesity43
and was monitored in our term infant birth cohort. The
delta BMI from birth until 2 years of age was correlated with
the mean of neonatal fS100A8-A9 levels while accounting
for confounding influences. There is a strong inverse rela-
tionship; children with low fS100A8-A9 levels show a
significantly stronger increase in their BMI over time
compared with children with high fS100A8-A9 levels
whose BMI at 2 years differs little from that at birth
(Figure 7I).
Collectively, these data indicate a clinically highly rele-
vant regulating impact of S100A8-A9 for the newborn’s
adaptation of intestinal immunity and suggest S100-
alarmins as a valuable immunomodulatory measure forealth and disease. (A) Left panels, representative images of
eonatal SI and LI tissue samples immunostained for S100A8
r of CD68þ LPMPs (blue dotted bar), S100A8-CD68þ LPMPs
nt mean counts in 4 high-power fields of n ¼ 6 control SI, n ¼
5 (Mann-Whitney U test). (B) Mean of first-week fS100A8-A9
nce of LOS (n ¼ 17). Box plots show medians and interquartile
ith/without fS100A8-A9 as predictor of LOS, with gestational
ates fed after birth with S100A8 or phosphate-buffered saline
ous injection of S aureus. (C) Experimental setup. (D) Survival
ma cytokine levels (each group n ¼ 7) and (F) bacterial burden
nt means ± SEM. CFU, colony-forming units. *P < .05, **P <
f body weights of male and female WT and S100a9–/– mice at
). P value determined per likelihood ratio test. (H) Body weight
oss-fostered during infancy (each group n ¼ 10–17). *P < .05,
nder-adjusted linear regression depicting a significant inverse
d the delta BMI from birth until 2 years of age in n ¼ 72 human
. r, Pearson’s correlation coefficient; P value of correlation.




ATthe prevention of frequent dysbiosis-linked short- and long-
term diseases.Discussion
Our knowledge about what programming of neonatal
immunity ensures optimal adaptation to the new extra-
uterine environment and what parameters determine such
programming is fragmented. By detailed cellular and mo-
lecular studies in mice and 2 human birth cohorts we
identified S100A8-A9 in the neonatal gut as a crucial host
factor contributing to the successful co-development of gut
mucosal immunity and the microbiota. We demonstrated
that fS100A8-A9 levels are physiologically high in healthy
term babies, particularly after VD compared with CS. Labor-
induced stress is obviously the driving force for fS100A8-A9
release as levels after secondary CS (with preceding labor)
are comparable to those after VD. We showed previously
that breastfeeding provides infants with a large amount of
S100A8-A923 and here identify LPMPs in the neonatal in-
testine as a second source of fS100A8-A9. The lower
S100A8-A9 levels in breast milk of mothers that gave birth
to a preterm infant,23 slower increase of feeding volumes
and higher CS rates are presumably the main reasons for
reduced fS100A8-A9 in preterm compared with term ba-
bies. Other factors like birth weight, Apgar score, diet, and
probiotics might also influence neonatal fS100A8-A9 and
are currently analyzed in a prospective multicenter clinical
study.
In our birth cohort, high fS100A8-A9 levels correlated
with a specific gut microbiota state characterized by a
strong expansion of Actinobacteria-like Bifidobacteriaceae
and growth restriction of Gammaproteobacteria-like
Enterobacteriaceae, implying an increase in health-
beneficial gut metabolic activity including enriching
short-chain fatty acid availability, although it is important
to recognize this is a prediction from taxonomic compo-
sition which future studies must validate experimentally.
Bifidobacteriaceae might contribute to the restriction of
Enterobacteriaceae by producing acetate.44 But for deeper
species resolution and assessment of the gut functional
potential future shotgun metagenomic analyses are
essential. Enterobacteriaceae include important neonatal
sepsis-causing opportunistic pathogens, eg, E coli,
Enterobacter, and Klebsiella species.9,10 E coli has even
been proposed as marker of gut dysbiosis associated with
diseases like NEC,8,45 childhood atopy,6 IBD,46–48 and
obesity.49 In murine neonates, endogenously produced
S100A8-A9 partly but enterally supplied S100A8-A9 via
breast milk completely prevented the intestinal over-
growth of Enterobacteriaceae. Herein, S100A8-A9 likely
acts in synergy with immunoregulatory human milk oli-
gosaccharides, which prevent the mucosal attachment of
pathobionts like E coli50 while encouraging the growth of
Bifidobacteriaceae.51
Our study demonstrates that S100A8-A9 in the intestine
has obviously a dual role of extended relevance for the
development of mucosal immunity. Directly after birth, un-
der noninflammatory conditions, the exposure to S100A8-A9 induced microbial tolerance in LPMPs by restricting
their LPS responsiveness in terms of Tnf and Il1b expression
(eg, against the first wave of microbial colonization). This is
similar to the S100A8-A9–mediated stress tolerization of
newborn monocytes found previously.17–19 After the
neonatal period (in mice at >3 days), the amplifier function
of S100A8-A919,34–36 applied by supporting the proin-
flammatory response of LPMPs (eg, in response to
expanding microbiota and for defending possible patho-
gens). Particularly, however, S100A8-A9 consistently
induced a regulatory LPMP phenotype with full effect of
high CX3CR1 levels, and Il10 and Tgfb1 expression espe-
cially when supplied enterally, which promoted the expan-
sion of Tregs. Our ex vivo as well as in vivo findings point to
IL-10 playing a crucial role for the S100-mediated regula-
tion of Tregs by LPMPs. The microbiome-shaping effect
might amplify the expansion of Tregs by increasing the
levels of commensal-derived butyrate.52 Potential direct
Treg-inducing activity of S100A8-A9 appears less relevant
as its extracellular half-life is only approximately 24
hours,35,53 whereas the Treg-promoting effect of a single
feeding of S100A8 at birth was not evident before day 10.
This is the first evidence that next to microbes also endog-
enous TLR-ligands like S100A8-A9 have crucial instructing
function for the newborn intestinal immune system. The
here-identified immunomodulatory effects of fS100A8-A9
explain well the resulting shaping effect on the microbiota
composition. CX3CR1, IL-10, and TGF-b as well as Tregs
have been demonstrated to be important factors controlling
the gut microbiota composition, specifically also the
expansion of Enterobacteriaceae.54–57 Interestingly, signs of
colitis in IL10R-deficient mice are absent during the first 2
weeks of life, while intestinal inflammation and macrophage
dysfunction begin during the third week, concomitant with
weaning.58 Thus, the immunoregulatory effects other than
IL-10 induction might be of particular relevance for the
S100-mediated impact on the gut microbial ecology.
The clinical relevance of S100-programming of neonatal
gut immunity is shown for NEC and LOS, frequent dysbiosis-
associated diseases in preterm infants. We observed virtu-
ally no expression of S100A8-A9 in the intestine of patients
with NEC. This finding is supported by a previous obser-
vation of unusually low fS100A8-A9 concentrations in the
meconium of patients with later NEC.59 In contrast, due to
the physiologically increased basal levels in neonates, which
moreover are developmentally controlled (GA and age)59,60
with high interindividual variation,61 fS100A8-A9 is no
valuable biomarker in NEC like in IBD of older children and
adults.22 In our cohort, low fS100A8-A9 levels reliably
predicted a high LOS risk even when controlling for GA.
Experimentally, 1-time feeding of S100A8 to S100a9–/– ne-
onates prevented fatal outcomes of later sepsis. It might
appear contradictory that there was only one E coli–positive
LOS case within the blood-culture positive subjects of our
preterm infant cohort while Enterobacteriaceae expand at
low fS100A8-A9 levels. On the other side, our study might
suggest a new perspective on the linkage between gut
dysbiosis and sepsis by suggesting both being separate
consequences of insufficiently S100-primed neonatal
December 2020 Calprotectin Ensures Gut Homeostasis 2143immunity that predisposes to unregulated immune re-
sponses to microbial challenges.17–19
The here-identified link between low neonatal fS100A8-
A9 levels and a disproportionate weight gain during child-
hood points to a role in dysbiosis-associated long-term
diseases. Skewed gut microbiota composition has been
shown to predispose to the development of obesity.7,41,42,49
In the mouse model, 1-time feeding of S100A8 after birth
prevented excessive weight gain in adolescent S100a9–/–
mice. Future clinical studies in humans will have to clarify
whether food supplement with S100A8-A9 during infancy
prevents the development of unfavorable gut microbiota
signatures and therewith associated diseases to promote
long-term health.
Collectively, our data demonstrate for the first time that
abundant fS100A8-A9 trains intestinal mucosal immunity
by regulating the inflammatory programming and cellular
development during infancy, which goes along with coloni-
zation by a favorable microbiota. Intestinal S100A8-A9
deficiency increases the risk of newborn individuals to
develop unfavorable gut microbiota signatures and associ-
ated diseases. Animal data suggest nutritional supplemen-
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Stool samples (n ¼ 517) were collected from 2 birth
cohorts of healthy term and preterm infants. Term infants
(n ¼ 72, Supplementary Table 1) were prospectively
enrolled at the Hannover Medical School from May 2015 to
June 2017. The inclusion criteria were being born healthy
and appropriate for gestational age (GA) with a GA of 37 0/
7 to 41 6/7 weeks, an Apgar score of 8 after 5 minutes,
and intended breast feeding as predominant diet. GA was
calculated on the basis of the mother’s last menstrual
period. When early ultrasound at 11 to 13 6/7 weeks of
gestation using fetal crown–rump length deviated by more
than 7 days, dating was done by ultrasound. After written
informed consent was obtained from parents, d1 and d2
stool samples were collected by medical staff from diapers
and after that by parents on d10, d30, and d90 and at 6 and
12 months. Infants from pregnancies that involved in vitro
fertilization, multiple gestations, births that resulted from
maternal trauma, and newborns with any congenital mal-
formations or chromosomal anomalies, with clinical or
laboratory signs of amnion infection syndrome or if the
mother or infant received any peripartal antibiotic therapy
were excluded. Cohort subjects were followed until 2.5
years of age. Metadata collected on maternal characteristics
were age and BMI at delivery and prepregnancy BMI. Child-
related data included the BMI (birth, d30, 3m, 6m, 1y, and
2y), diet (exclusive breastfeeding, mixed feeding with for-
mula, age at introduction of solid food) history of allergies,
infections, antibiotics and inhalations during the first year
of life. Information on life circumstances included the
presence of siblings, smoking status of the parents, pets,
and residence (county/urban).
The birth cohort of preterm infants was established
between January 2012 and January 2017 and included 49
preterm infants born at a GA of 23 0/7 to 31 6/7 weeks in
the Neonatal Intensive Care Unit of the Department of Pe-
diatrics at the University of Lübeck (Supplementary
Table 2). Infants with lethal malformations or congenital
anomalies of the gastrointestinal tract were excluded. LOS
was defined as sepsis starting after 72 hours of life. LOS was
diagnosed with the occurrence of 2 clinical signs of sys-
temic inflammatory response and 1 laboratory sign. Clinical
signs of LOS included temperature >38C or <36.5C,
tachycardia >200/min, new onset or increased frequency
of bradycardias or apneas, hyperglycemia >140 mg/dL,
base excess <10 mval/L, changed skin color, and
increased oxygen need. Laboratory signs of LOS were C-
reactive protein >10 mg/L, platelet count <100/nL,
immature/total neutrophil ratio >0.2, and white blood cell
count <5/nL. Blood culture confirmed LOS was defined as
clinical LOS with bacterial growth in the blood culture,
which was taken before commencing antibiotic therapy.
LOS occurred in n ¼ 22 cases at a mean age of 14.8 days ±
4.9, from which 11 were blood culture proven (Staphylo-
coccus haemolyticus 5, Staphylococcus. epidermidis 4,
Escherichia coli 1, Enterococcus faecalis 1). Fecal samples
were collected from the preterm birth cohort on days 1 to 7,
8 to 12, 13 to 19, and 20 to 30 by medical staff from diapers
or after rectal enema with 37C NaCl 0.9% solution. Stool
was immediately stored at20C, and transferred to 80C
within 3 days.
Human intestinal tissue samples were obtained upon
written informed consent from n ¼ 8 adult patients and n ¼
18 newborn infants and included SI and LI resections
(Supplementary Table 3). Biopsies in adults were per-
formed due to the exclusion of malignancies or IBD or in the
context of ileostomy or bile duct carcinoma and served as
adult controls. Intestinal tissue from newborn infants was
resected due to the diagnosis of NEC (n ¼ 8) or in the
context of inborn atresia, perforation, stenosis, volvulus, or
ileostomy (n ¼ 10). Biopsies of the latter served as neonatal
intestinal controls. The tissue was formalin-fixed and
paraffin-embedded and used for immunofluorescence
microscopy.
Ethics Statement
Protocols and usage of human biomaterial were
approved by the Institutional Review Board of the Hann-
over Medical School (no. 6031-2015 and 3381-2016) and
University of Lübeck (no. AZ15-304). Written informed
consent was obtained from parents or legal representatives
on behalf of the infants enrolled in our study. Mouse ex-
periments were carried out in accordance with German
Animal Welfare Legislation and performed as approved by
the Lower Saxony State Office for Consumer and Food
Safety, Germany (approval no. 33.9-42502-04-15/1951 and
33.12-42502-04-15/1969).
Reagents and Bacteria
LPS (E coli 055:B5) was purchased from Sigma (Tauf-
kirchen, Germany). Murine S100A8 was recombinantly
expressed in E coli BL21(DE3) and purified as described
earlier.1Klicken oder tippen Sie hier, um Text einzugeben. S
aureus strain Newman, GenBank accession number
AP009351.1, was used and inoculated 1:100 in Todd-
Hewitt-Bouillon (Roth, Karlsruhe, Germany) and incubated
at 37C until late-logarithmic phase was reached (OD600 ¼
0.7–0.8). Suspensions were adjusted to a concentration of
1  1010/mL and stored at 80C. Infection dose was
controlled by serial dilutions and plating blood-agar (Oxoid,
Wesel, Germany) for colony-counting.
Fecal S100A8-A9 (fS100A8-A9)
Fecal sample aliquots were suspended in extraction
buffer adopted from Hycult Biotech’s H325 Human Cal-
protectin enzyme-linked immunosorbent assay (ELISA) kit.
Suspensions were thoroughly vortexed, filtered through a
100-mm cell strainer, and then incubated on a shaker on ice
for 20 minutes. The homogenates were centrifuged for 20
minutes at 10,000g at 4C. The upper portion of the su-
pernatants was pipetted off, frozen, and stored at 80C
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until quantification of fS100A8-A9 by an in-house ELISA as
described previously.1,2
Immunofluorescence Microscopy
Human paraffin-embedded intestinal tissues sections
were deparaffinized in Roti-Histol (Roth), rehydrated and
subjected to heat-induced antigen retrieval in citrate buffer.
In NEC samples, resection margins unaffected from necrosis
and severe inflammation were analyzed. Before antibody
staining, the tissue was washed and blocked with 5% skim
milk powder in tris-buffered saline (TBS) to minimize
nonspecific binding. The slides were stained overnight at
4C in the dark with mouse anti-human CD68 monoclonal
antibody (mAb) (M0814, Dako, Hamburg, Germany) and
rabbit anti-human S100A8 polyclonal antibody (purified by
T.V.) followed by AlexaFluor488 donkey anti-mouse and
AlexaFluor555 donkey anti-rabbit secondary antibodies
(both Life Technologies, Darmstadt, Germany). Tissue was
mounted in VECTASHIELD Antifade Mounting Medium with
40,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories,
Burlingame, CA). Images were acquired using the Zeiss
Axioplan 2 fluorescence microscope with a Zeiss EC Plan-
Neofluar 10x/0.3 objective and a Zeiss EC Plan-Neofluar
40x/0.75 Ph2 objective, the AxioCam Color camera and
AxioVision 40 v4.8.2 imaging software from Zeiss (Jena,
Germany). The number of CD68þ and S100A8þ cells in
human intestinal tissues sections was determined per high-
power field by manual counting performed by 2 blinded
observers.
Murine colon tissue was embedded in Tissue-Tek
O.C.T. Compound (Sakura Finetek, Torrance, CA) without
prior fixation, frozen on dry ice, and stored at 80C.
Cryosections (8 mm) were fixed with acetone and stored
at 20C. Sections were rehydrated in TBS supplemented
with 0.1% Tween20 (TBST) and blocked with 5% rat
serum. For immunostaining, the following antibodies were
used: rat anti-mouse forkhead box P3 (FoxP3) mAb (FJK-
16s, eBioscience, San Diego, CA), rat anti-mouse CD3 mAb
(17A2, purified in the Förster laboratory, Hannover,
Germany), rat anti-mouse CD4 mAb (GK1.5, purified in
the Förster laboratory), rat anti-mouse F4/80 mAb (BM8;
Biolegend, San Diego, CA), and mouse anti-mouse Cx3cr1
mAb (SA011F11, BioLegend). Images were acquired using
an Olympus BX61 epifluorescence microscope. For the
analysis of Cx3cr1 expression on F4/80þ LPMPs, at least
5 randomly selected images acquired from proximal, mid
and distal LI sections prepared from 2 WT and 2
S100a9/ neonatal mice (day 10) were analyzed per
condition. The same exposure times were used for the
acquisition of the read-out channel for Cx3r1 staining.
The intensity of Cx3cr1 expression was measured by
defining regions of interest (ROIs) encompassing F4/80-
stained areas and measuring the maximum fluorescence
intensity of the Cx3cr1 signal in ROIs. For the analysis of
Tregs, CD3þCD4þ T cells with a FoxP3-positive nucleus
were counted manually by 2 blinded observers.
Mice and Mouse Studies
The following mouse strains used in this study were
housed under specific pathogen-free conditions at the
Central Animal Facility at Hannover Medical School. The
Foxp3-eGFP reporter mouse B6.Cg-Foxp3 tm1 Mal/J was
obtained from Jackson Laboratory (Bar Harbor, ME) and
used for the isolation of naïve CD4þ T cells from adult
spleens. C57BL/6J WT mice purchased from Charles River
(Sulzfeld, Germany) and S100a9/ mice (C57BL/6 back-
ground)3 were constantly bred and litters used randomly at
indicated ages to harvest colon contents, LIs, mesenteric
lymph nodes (mLN), and celiac lymph nodes (cLN). No
animals needed to be excluded from the studies. WT and
S100a9/ mothers were co-housed for at least a week
before and after mating until day 18 of pregnancy and then
separated for delivery. In indicated experiments, S100a9/
pups were supplemented within 24 hours after birth either
by IP injection of 2.5 mg S100A8 in 20 mL phosphate-
buffered saline (PBS) or enteral feeding of 5 mg S100A8 in
20 mL PBS. Mice supplemented with PBS alone served as
controls. For cross-fostering experiments, mating of WT and
S100a9/ mice was terminated to exchange litters within
12 hours after birth.
Isolation of LPMPs From the Murine Colon
LPMPs were isolated from harvested murine LIs using a
modified protocol published elsewhere.4 After dissection,
the colon was opened longitudinally, the stool was collected
and the tissue was thoroughly washed in ice-cold PBS. In
day 3 and day 10 neonates, 3 to 4 LIs were pooled for one
experiment. To remove intestinal epithelial cells, the tissue
was cut into 0.5-cm pieces and incubated in prewarmed
PBS supplemented with 2 mM EDTA for 15 minutes at 37C
with agitation. Subsequently, the tissue was repeatedly
shaken, minced, and digested for up to 60 minutes at 37C
under constant agitation in RPMI medium (Lonza, Basel,
Switzerland) containing 10% fetal calf serum (FCS), 1%
penicillin/streptomycin, 75 mg/mL liberase, and 30 U
DNase I (both Sigma). The digested tissue was filtered
through a 100-mm cell strainer followed by a 70-mm cell
strainer. Thereby isolated lamina propria mononuclear cells
(LPMCs) were pelleted and resuspended in PBS containing
2 mM EDTA and 2% bovine serum albumin (FACS buffer)
and used for cell number determination, flow cytometry
studies and cell sorting. LPMPs were sorted at the central
Research Facility Cell Sorting at the Hannover Medical
School, either on FACSAria Fusion and FACSAria IIu (both
BD Biosciences, Heidelberg, Germany) or on MoFlo XDP
(Beckmann-Coulter, Krefeld, Germany). Therefore, LPMPs
were stained as described below and sorted by gating on
live CD45þCD11bþF4/80þ/interm cells. The purity of isolated
LPMPs was >90%. For the preparation of cytospins, LPMPs
were seeded on superfrost slides and centrifuged at 300g
for 5 minutes. Cells were fixed in 2% paraformaldehyde
(PFA) and stained with hematoxylin/eosin. Remaining
LPMPs were used for gene expression studies and ex vivo
stimulation assays.
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Flow Cytometry
All staining panels included a Fixable Viability Dye
eFluor 506 (eBioscience) to exclude dead cells as well as
CD16/CD32 (2.4G2, BioLegend) for blocking purposes.
Staining was performed for 30 minutes in the dark at 4C.
After staining cells were fixed with 2% PFA.
LPMPs
For the analysis of F4/80hiCD11bþ/-Ly6G-CD11c- YS-
LPMPs and F4/80þCD11bþLy6G-CD11c- BD-LPMPs,
colonic LPMC single-cell suspensions were stained with
rat anti-mouse CD45 mAb (30F-11), rat anti-mouse F4/80
mAb (BM8), hamster anti-mouse CD11c mAb (N418), rat
anti-mouse CD11b mAb (M1/70) (all eBioscience) and rat
anti-mouse Ly6G mAb (1A8, BioLegend) and gated as
illustrated in Supplementary Figure 4A and B.
Tregs
For the analysis of Tregs, single-cell suspensions of
colonic LPMCs, mLNs and cLNs were first stained extra-
cellularly using rat anti-mouse CD45 mAb (30-F11), ham-
ster anti-mouse CD3e mAb (145-2C11) and rat anti-mouse
CD4 mAb (RM 4-5) (all eBioscience). For intracellular
staining, cells were fixed in 2% PFA for 30 min at room
temperature. Subsequently, cells were stained with rat anti-
mouse FoxP3 mAb (FJK-16s, eBioscience) in FACS buffer
with 0.5% saponin and 0.2% Tween20 for another 30 min
at 4C in the dark. Gating was done as shown in
Supplementary Figure 5A.
Data Acquisition and Analyses
All flow cytometry analyses were performed using a
FACS Canto II flow cytometer (BD Biosciences). Data were
analyzed using DIVA software v8.0.1 (BD Biosciences) and
Kaluza software v2.1 (Beckman Coulter, Miami Lakes, USA).
Cell Culture Conditions
Sorted LPMPs were seeded at a concentration of 1  106
cells/mL in RPMI medium supplemented with 10% FCS, 1%
L-glutamin and 1% penicillin/streptomycin. After overnight
culture LPMPs were stimulated for 4 hours with 100 ng/mL
LPS. Control cells were incubated with PBS, respectively.
Subsequently, LPS-stimulated cells were harvested and
processed for gene expression studies.
In order to analyze the Treg-inducing capacity of WT and
S100a9/ LPMPs, naïve CD4þ T cells were isolated from cell
suspensions prepared from spleens of adult Foxp3-eGFP re-
porter mice by using the Naïve CD4þ T Cell Isolation Kit from
Miltenyi Biotec (Bergisch Gladbach, Germany) according to
the manufacturer’s instructions. Naïve T cells were co-
cultured with LPMPs at ratios of 10:1 or 5:1 with a total cell
concentration of 1  106 cells/mL in plates coated with 10
mg/mL of hamster anti-mouse CD3e mAb (145-2C11,
eBioscience) and in the presence of 2 mg/mL of hamster anti-
mouse CD28 mAb (37.51, eBioscience) and 10 ng/mL of IL-2
(Biolegend) without and with addition of 5 ng/mL of re-
combinant TGF-b (R&D, Minneapolis, MN) and 20 ng/mL of
recombinant IL-10 (PeproTech, Rocky Hill, NJ). Cells were
harvested after 4 days, stained with hamster anti-mouse
CD3e mAb (145-2C11), rat anti-mouse CD4 mAb (RM 4-5)
and Fixable Viability Dye eFluor 506 (all eBioscience) and
analyzed by flow cytometry to determine the proportion of
GFP-expressing Foxp3þ Tregs of CD3þCD4þ T cells.
Quantitative Real Time PCR (qRT-PCR)
Total RNA was isolated using the NucleoSpin RNA II kit or
NucleoSpinRNAXSkit (bothMacherey-Nagel, Düren, Germany)
according to the manufacturers instructions. Complementary
DNA (cDNA)was synthesized from40 ng of total RNA using the
SuperScript VILO Master Mix (Invitrogen, Carlsbad, CA). qRT-
PCR was done as described previously.5 The murine primers
used for qRT-PCRs were Gapdh (F, GGACACTGAGCAAGA-
GAGGC; R, TTATGGGGGTCTGGGATGGA), Tnf (F, GATCGGTCC
CCAAAGGGATG; R, GTGGTTTGTGAGTGTGAGGGT), Il1b (F, TGT
CTTGGCCGAGGACTAAGG; R, TGGGCTGGACTGTTTCTAATGC),
Il10 (F, GGGTTGCCAAGCCTTATCG; R, TCTCACCCAGGGAATT-
CAAATG), and Tgfb1 (F, AGGAGACGGAATACAGGGCT; R,
ATGTCATGGATGGTGCCCAG). Sample data are presented as the
fold change (FC) in expression compared with the controls as
determined by the comparative DCt method or relative to the
housekeeper Gapdh.
Microbiological Analysis of Murine Fecal
Samples
Colon and cecum content were collected and suspended
at 1 mL PBS/g feces. Serial dilutions were plated on Luria/
Bertani agar (Roth) and incubated overnight under aerobic
conditions at 37C and 10% CO2 to determine the numbers
of CFU/g feces. For the selective growth of Enterobacteri-
aceae, diluted samples were plated on MacConkey agar
(AppliChem, Darmstadt, Germany). Presumptive identifica-
tion of E coli was made based on its characteristic colony
morphology on the MacConkey agar (dry, donut shaped,
dark pink in color, and surrounded with dark pink area).
Bioinformatics of 16S rRNA Gene Sequencing
Data
The raw fastq files were processed using mothur version
1.40.5.6 After generation of contigs, sequences containing
ambiguous bases and sequences longer than 500 base pairs
were removed. With the primer sequences from the MiSeq
sequencing experiment, a custom reference alignment was
generated using the SILVA reference version 132.7 Se-
quences containing more than 8 homo polymers were
excluded and sequences of nonbacterial origin removed.
Chimeras were detected by the VSEARCH algorithm8 as
implemented in mothur. Classification of sequences was
performed using the Greengenes database gg_13_8_99.9
Sequences were clustered into operational taxonomic
units (OTUs) according to their taxonomic assignment. The
analysis after pre-processing in mothur was performed in R
(version 3.6.1), mainly relying on the phyloseq package.10
Following mapping of 16S reads to OTUs and binning at
taxonomic class and family levels, total mapped read
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abundances were down sampled using the rarefaction
toolkit (RTK)11 at default settings to account for differences
in sampling depth as well as to compute alpha diversity
metrics. For metagenome inference amplicon sequences
were filtered, quality controlled, and taxonomically assigned
using the LotuS pipeline.12 Default parameters for the small
subunit ribosomal ribonucleic acid and the MiSeq platform
were used, while SILVA, Greengenes and HITdb (v1.00)13
were used incrementally for taxonomic classification.
Resulting abundance tables were normalized using RTK to
95% of the minimal column sum. Metagenome functional
content was inferred from the raw amplicon sequences and
processed taxonomic abundances using the PICRUSt2
method (v2.3.0-b).14 MetaCyc pathway abundances were
generated using the default map files and functional data-
bases.15 For nested model comparisons taxon abundances
and MetaCyc pathway abundances (rarefied reads) were
modeled individually using mixed effect models (R lme4
package) with fS100A8-A9, MOD, and age in days as fixed
effects, with child identity as a random effect so as to ac-
count for the longitudinal nature of the data. Restricted
maximum likelihood (REML) approximations were disabled
to ensure likelihood ratio tests for nested model compari-
sons are accurate. For each tested variable (fS100A8-A9,
MOD, age) a model omitting this feature was constructed
and the 2 models compared in a likelihood ratio test (R
lmtest package). In addition, each tested variable was
directly compared against each tested feature (using a
Mann-Whitney U [MWU] test for MOD and a Spearman test
for age, and fS100A8-A9), with nonparametric directional
effect sizes calculated as Spearman rho or Cliff’s delta (R
orddom package). Features were considered to be strongly
and significantly affected by each feature if Benjamini-
Hochberg–corrected P values for both nested model and
simple test fulfilled false discovery rate (FDR) <0.1, and if
absolute effect size exceeded 0.2.
Statistical Analysis
Statistical tests applied for 16S rRNA gene sequencing
data analysis are described previously. Group comparison of
fS100A8-A9 levels and proportions of S100A8þ LPMPs in
human tissue samples was performed by applying the 2-
tailed MWU test. Age dependency of fS100A8-A9 levels
was evaluated by running a Kruskal-Wallis test including
post hoc Dunn’s multiple comparison test. To test for dif-
ferences between WT and S100a9/ mice in gene expres-
sion or in fraction of Tregs measured at different ages, a
nested model test was further used building generalized
linear models (R lme4 package) of measured data using a
Gamma distribution error model and setting zero values to a
pseudocount floor of 1-e-10. Models with age and genotype
were contrasted to models containing age only to test for
main effect of genotype. Models with age, genotype, and an
interaction term between them were contrasted to models
containing age and genotype only to test for interaction
effect between age and genotype. Models were compared
using the R lmtest package. To test for differences between
control and supplemented mice in gene expression or in
fraction of Tregs, a nested model test was further used
building generalized linear models (R lme4 package) of
measured data using a Gamma distribution error model and
setting zero values to a pseudocount floor of 1-e-10. Models
with age and genotype were contrasted to models contain-
ing age only to test for main effect of supplementation.
Models with age, supplementation, and an interaction term
between them were contrasted to models containing age
and supplementation only to test for interaction effect be-
tween age and supplementation. Models were compared
using the R lmtest package. To test for differences between
WT and S100a9/ mice in proportion of Tregs, a nested
model test was further employed building generalized linear
models (R lme4 package) of proportions of Treg to CD3þ
cells using a binomial error model. Models with age and
genotype were contrasted to models containing age only to
test for main effect of genotype. Models with age, genotype
and an interaction term between them were contrasted to
models containing age and genotype only to test for inter-
action effect between age and genotype. Models were
compared using the R lmtest package. Comparisons in co-
culture assays and cross-fostering settings were evaluated
by two-tailed t-tests. The difference between genotypes
resp. intervention groups in the proportion of
Enterobacteriaceae-positive fecal samples was tested by
using the sign test. The association between fS100A8-A9
levels and the occurrence of LOS was assessed by calcu-
lating odds ratios and their 95% confidence intervals and by
using a nested model test building generalized linear models
(R lme4 package) of measured data using a Gamma distri-
bution error model and setting zero values to a pseudocount
floor of 1-e-10. The model with fS100A8-A9 and GA was
contrasted to a model containing GA only to test for main
effect of fS100A8-A9. Kaplan-Meier survival curves were
generated using the Mantel-Cox test. The fS100A8-A9 levels
of human term and preterm infants delivered by VD and CS
and the body weight of WT and S100a9/ mice was
modeled against the fixed factor time (age). Linear models
were fitted using the lm function of the standard R-package
stats. Likelihood ratio tests of the full model against the
control model without the fixed effect of MOD respective
genotype were performed to determine the P-value of the
difference between the mouse strains regarding gain of
weight over time. Bivariate linear regression was used to
assess how the mean of fS100A8-A9 during the first 10 days
of life relates to the delta of the BMI from birth until 2 years
of age of the children of the birth cohort of term human
infants (Supplementary Table 1). We obtained crude and
multivariable-adjusted estimates of this association. The
multivariable-adjusted models included terms for maternal
age and BMI at delivery, maternal prepregnancy BMI,
birthweight (all continuous variables), offspring sex (boy or
girl), diet (exclusive and mixed breastfeeding), antibiotics
during the first year of life (yes/no), presence of siblings
(yes/no), smoking status of the parents (yes/no), pets (yes/
no), and residence (county/urban). P values < .05 were
judged to be significant.
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